Therapeutic Area: Gastroenterology
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Faes Farma S.A.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 12, 2020
Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.